Croda International, a century-old company, has a remarkable story to tell. From its humble beginnings in a former waterworks in rural East Yorkshire, it has grown into a FTSE 100 powerhouse. Now, as it celebrates its centenary, Croda's impact on a rare degenerative condition affecting young boys is being highlighted. This story is brought to life in the Hollywood film, 'Lorenzo's Oil', based on the real-life efforts of the Odone family.
The film depicts the story of Lorenzo Odone, a boy from Hull, who was diagnosed with adrenoleukodystrophy (ALD) in 1984. Doctors predicted a grim future, but his parents refused to give up. They embarked on a tireless quest to find a treatment, which led to the creation of Lorenzo's oil. Two streets in Hull now bear the names 'Lorenzo's Way' and 'Suddaby Close', paying tribute to their heroic efforts.
Croda's involvement began with a unique approach. Despite lacking formal scientific training, Lorenzo's father, Augusto, studied medicine and biochemistry. He formulated a potential treatment for ALD using acids from olive and rapeseed oils. The Odones approached Croda, which had large manufacturing plants in Hull, and the chemist Don Suddaby, who distilled the formula into Lorenzo's oil. Suddaby, who played himself in the film, passed away shortly after its release.
Keith Layden, a former Croda employee, recalls the company's role in this groundbreaking work. He explains how the request for assistance from Augusto Odone led to a collaboration with Keith Coupland, the technical director. This partnership resulted in the creation of Lorenzo's oil, a journey that took Croda from Hull to Hollywood.
Croda, founded in 1925 by George Crowe and Henry Dawe, initially produced lanolin from sheep's wool in a former waterworks in Rawcliffe Bridge. Over time, the company expanded into various products and moved its headquarters to Cowick Hall in East Cowick. Today, Croda is a leading provider of ingredients for skincare, pharmaceuticals, homecare, and agriculture.
The company's impact on healthcare is significant. Croda's involvement in developing Lorenzo's oil sparked a new focus on healthcare. In 1997, they established a dedicated healthcare division, which has since become a major part of their business. Croda's contributions have benefited millions, notably during the COVID-19 pandemic with the production of the first mRNA-based vaccine.
Despite the success, questions arose about the efficacy of Lorenzo's oil for patients already suffering from the disease. Scientific studies indicated that it was not effective for those already ill but could prevent illness in those genetically predisposed to developing symptoms. However, the British leukodystrophy charity, Alex TLC, suggests that the available evidence does not prove Lorenzo's oil as a preventative measure, but it may benefit boys with asymptomatic ALD.
Today, Lorenzo's oil is still produced, though it was never a commercially viable venture for Croda. Layden emphasizes that the company's motivation was a sense of purpose, not just financial gain. Croda's journey from a small producer to a major player in the FTSE 100 showcases the power of innovation and a commitment to making a difference.
